Approach to increasing the platelet count in ITP

These platelet count thresholds are intended as a guide; some individuals with a platelet count <20,000 to 30,000/microL may reasonably choose not to receive treatment, and some individuals with additional bleeding risk factors may choose to receive treatment at higher platelet counts (up to 50,000/microL). We generally prefer glucocorticoids for initial therapy; we reserve IVIG (or anti-D) for those who have a contraindication to or intolerance of glucocorticoids or who require a more rapid increase in platelet count. Refer to a separate algorithm for treatment of bleeding. Refer to UpToDate for management of comorbidities, the importance of addressing other bleeding risk factors, decision-making between different therapies, and dosing and administration of specific medications.

ITP: immune thrombocytopenia; IVIG: intravenous immune globulin; TPO: thrombopoietin.
* Many patients with platelet counts <20,000 to 30,000/microL do not require treatment.
¶ The interval for rechecking the platelet count is individualized based on the patient's clinical status, typically ranging from a few days to a week. Responses to glucocorticoids typically occur within a few days (range, 2 to 14 days); responses to IVIG (or anti-D) can occur within 1 to 3 days.
Δ Splenectomy is generally deferred for at least 12 months after diagnosis (if possible), in case a spontaneous remission occurs.
◊ Other treatments include fostamatinib, danazol, other immunosuppressive agents, or combination therapy.
§ The risk of adverse drug effects must be balanced against the benefit of raising the platelet count in an asymptomatic patient (refer to UpToDate for discussion).

Graphic 130855 Version 2.0

خرید پکیج

Approach to increasing the platelet count in ITP